lei
Lv01
0 积分
2023-10-02 加入
-
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
1小时前
已完结
-
A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer: Presentation of safety data
2小时前
已完结
-
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
2小时前
已完结
-
Translocation of vaginal and cervical low-abundance non-Lactobacillus bacteria notably associate with endometriosis: A pilot study
8个月前
已完结
-
Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis
10个月前
已完结
-
Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition
10个月前
已完结
-
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
10个月前
已完结
-
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
10个月前
已完结
-
Pembrolizumab Plus Chemotherapy in Japanese Patients With Persistent, Recurrent or Metastatic Cervical Cancer: Results From KEYNOTE ‐826
10个月前
已完结
-
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
11个月前
已完结